Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | CHKA | P35790 | 3/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31093121 | 0.94 | SLC6A4 (0.62) | SLC6A4SLC6A3ALDH1A1KMT2AGFER | |
| SCHEMBL1903553 | 0.87 | ALDH1A1 (0.62) | SLC6A4SLC6A3ALDH1A1KMT2AGFER | |
| SCHEMBL31093170 | 0.87 | SLC6A4 (0.69) | SLC6A4SLC6A3ALDH1A1KMT2AGFER | |
| SCHEMBL9779110 | 0.85 | ALDH1A1 (0.65) | SLC6A4SLC6A3ALDH1A1KMT2AGFER | |
| SCHEMBL31093108 | 0.82 | KMT2A (0.74) | SLC6A4SLC6A3ALDH1A1KMT2AGFER | |
| SCHEMBL31093117 | 0.78 | SLC6A4 (0.59) | SLC6A4SLC6A3HTR7SIGMAR1 | |
| SCHEMBL31093178 | 0.77 | SLC6A4 (0.54) | SLC6A4SLC6A3ALDH1A1SIGMAR1KDM4E | |
| SCHEMBL31092974 | 0.77 | SLC6A4 (0.54) | SLC6A4SLC6A3ALDH1A1KMT2AGFER | |
| SCHEMBL31092907 | 0.76 | SLC6A4 (0.57) | SLC6A4SLC6A3ALDH1A1KMT2AGFER | |
| SCHEMBL31092931 | 0.76 | SLC6A4 (0.57) | SLC6A4SLC6A3ALDH1A1KMT2AGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287009-A1 | AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME | INFINEUM INTERNATIONAL LIMITED (GB) | 2024-08-29 | — | — | US | disclosed |
| EP-4410772-A2 | AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME | Infineum International Limited (GB) | 2024-08-07 | — | — | EP | disclosed |
| CN-118440229-A | Amine functional monomers and methods of making the same | 英菲诺姆国际有限公司 | 2024-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287009-A1 | AMINE-FUNCTIONAL MONOMERS AND METHODS OF MAKING SAME | AMD1, HNMT, MAT1A | SLC6A4 2274/4885SLC6A3 2219/4885ALDH1A1 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.